Abstract 40P
Background
Recent evidence suggests that breast cancer may have population-specific characteristics, including differences in the tumour immune microenvironment (TME). Immune cell markers in the TME, particularly CD8, may have utility as predictive and prognostic biomarkers, but there is conflicting evidence from previous studies. The aim of this study was to determine the prognostic utility of immune cell immunohistochemistry markers in tumor samples from a cohort of breast cancer patients from Malaysia.
Methods
We obtained digitized whole slide images of breast tumour tissue samples stained for CD3, CD4, CD8, and PD-L1 markers for 576 breast cancer patients from Subang Jaya Medical Centre, a Malaysian private hospital. These patients were included in the Malaysian Breast Cancer (MyBrCa) study cohort, and thus multi-omics data were also available for analysis for each patient. We also obtained overall survival data from the Malaysian national registry for this group of patients, with a median follow-up time of 68 months.
Results
We compared the intra-tumoral scores for each marker to overall survival data and found that the scores for CD3, CD4, and CD8, but not PD-L1, were positively associated with overall survival, particularly for patients with triple-negative breast cancer (TNBC). Additionally, the CD3, CD4, and CD8 scores were not associated with tumour mutational burden (TMB) or neoantigen load and had a negative correlation with copy number aberrations.
Conclusions
Our results suggest that intra-tumoral markers for T-cells are indicative of good prognosis in Asian breast cancer. Our results also suggest that the TME in Asian breast cancer may be shaped by non-canonical pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
Cancer Research Malaysia, Yayasan PETRONAS, Yayasan Sime Darby, Scientex Foundation, Estee Lauder Companies, Vistage Malaysia, Newton-Ungku Omar Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract